Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.
bluebird bio Inc. announced a licensing agreement Jan. 7 with privately held Inhibrx LLC to use the latter’s proprietary single domain antibody (sdAB) platform to optimize CAR-T therapeutic candidates against multiple cancer targets
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?